We advised Beacon Biosignals, a leading computational neurodiagnostics and electroencephalogram (EEG) analytics company, on its acquisition of the research and development business of Dreem SAS, a Paris-based pioneer in at-home sleep monitoring.

The acquisition sets the stage for clinical trial assessments at scale via the integration of Dreem’s hardware with Beacon’s next-generation EEG analytics platform.

Lawyers from our restructuring team in Paris led the transaction, with support from our antitrust practice.

We advised Fresenius Kabi, a global health care company, on the divestment of its plant in Halden, Norway, to HP Halden Pharma AS, a company of the Prange Group.

The transaction enables Fresenius Kabi to further execute its Vision 2026 strategy, a comprehensive, global framework for sustainable growth and cost and efficiency improvements.

Lawyers in our Frankfurt office led the transaction, with support from our Berlin, Hamburg, and Munich offices and our antitrust, employment, finance, and regulatory practices.

We advised Kaiser Foundation Hospitals on its launch of Risant Health, a newly formed company designed to expand value-based care in community-based health systems, and Risant’s first acquisition of Geisinger Health, a health system.

Risant plans to acquire up to five additional health systems in the next five years to become a US$30 to US$35 billion annual revenue company.

Lawyers in our Washington, D.C. and New York offices led the transaction, with support from our Denver, Los Angeles, Miami, and Philadelphia offices and our antitrust, employee benefits, employment, environment, health, infrastructure and projects, intellectual property, privacy and cybersecurity, real estate, and tax practices.

We advised Novartis on its acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, for up to US$3.5 billion, including US$300 million of contingent value rights (CVRs).

The transaction expands Novartis’ renal portfolio with the addition of two late-stage assets to treat rare kidney diseases.

Lawyers in our Washington, D.C. office led the transaction, with support from our Amsterdam, London, Los Angeles, New York, Philadelphia, and San Francisco offices and our employee benefits, employment, FDA, intellectual property, litigation, privacy and cybersecurity, real estate, and tax practices.